Meloxicam

Overview

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It works by inhibiting the synthesis of prostaglandins, which play a key role in inflammation.

API suppliers (20)

Suppliers of Meloxicam evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• QUIMICA SINTETICA SASpain1 active DMF GMP on record
• BIDACHEM SPAItaly1 active DMF GMP on record
• DERIVADOS QUIMICOS SAUSpain1 active DMF
• SHANDONG XINHUA PHARMACEUTICAL CO LTDChina1 active DMF GMP on record
• Ipca Laboratories LimitedIndia1 active DMF GMP on record
• Apex Healthcare LimitedIndia1 active DMF
• Cipla USA, Inc.USA1 active DMF
• ANONIMA MATERIE SINTETICHE AND AFFINI (AMSA) SPA1 active DMF
• ARCH PHARMALABS LTDIndia1 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• Unichem Laboratories Ltd.India1 active DMF GMP on record
• UNIMARK REMEDIES LTDIndia1 active DMF
• SWATI SPENTOSE PRIVATE LTDIndia1 active DMF
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)Spain
• SICHUAN SANCHINE SUNNYHOPE PHARMACEUTICAL CO LTD
• ESTEVE QUIMICA SA GMP on record
• DR REDDYS LABORATORIES LTD GMP on record
• Micro Labs Ltd India
• Cadila Pharmaceuticals LimitedIndia GMP on record

EU CEP holders (10)

Companies holding a valid EU Certificate of Suitability (CEP) for Meloxicam, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (31 approved US products), the latest listed US patent on Meloxicam expires 31 Jul 2041. Generic API sourcing typically opens up once these lapse.

Therapeutic areas